Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2000-09-29
2011-11-22
Bunner, Bridget E (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S141100, C514S014300, C514S014500, C514S014900
Reexamination Certificate
active
08062638
ABSTRACT:
Provided herein is an animal having a persistent hypercoagulable state by implanting a cell, for example a tumor cell, in which the gene of human tissue factor is implanted to an experimental animal such as a mouse and then growing the cell, thereby persistently supplying human tissue factor to the experimental animal. This animal model is useful for research and development of therapeutic agents for diseases having a persistent hypercoagulable state. Also provided are preventive or therapeutic agents for diseases having a persistent hypercoagulable state, a hypercoagulable state resulting from infections, venous thrombosis, arterial thrombosis, and diseases resulting from the hypertrophy of vascular media, the agent comprising an antibody against human tissue factor (human TF) as an active ingredient.
REFERENCES:
patent: 5346991 (1994-09-01), Roy et al.
patent: 5879677 (1999-03-01), del Zoppo
patent: 5986065 (1999-11-01), Wong et al.
patent: 6287794 (2001-09-01), Safar et al.
patent: 6677436 (2004-01-01), Sato et al.
patent: 0 278 776 (1988-08-01), None
patent: 1 069 185 (2001-01-01), None
patent: 8-217799 (1996-08-01), None
patent: WO 88/07543 (1988-10-01), None
patent: WO 88/07543 (1988-10-01), None
patent: WO 88/09817 (1988-12-01), None
patent: WO 88/09817 (1988-12-01), None
patent: WO 98/40408 (1998-09-01), None
Eskens, F., “Angiogenesis inhibitors in clinical development; where are we now and where are we going?”, 2004, Brit. J. Cancer, vol. 90: pp. 1-7.
Weiner, L. et al., “An overview of Monoclonal Antibody Therapy of Cancer”, 1999, Sem. in Oncol., vol. 26: pp. 41-50.
Asakura et al, Thrombosis Research, 1995, vol. 80, No. 3, pp. 217-224.
Randolph, G. et al. “Role of Tissue Factor in Adhesion of Mononuclear Phagocytes to and Trafficking Through Endothelium in Vitro,” Blood (Dec. 1, 1998), vol. 92, No. 11, pp. 4167-4177.
Giesen, P. et al. “Blood-borne tissue factor: Another view of thrombosis,” Proc. Natl. Acad. Sci. (Mar. 1999), vol. 96, pp. 2311-2315.
Nakayama, T. et al., (1999) vol. 39, No. 4, 298-302.
Drake, T. et al. “Functional Tissue Factor is Entirely Cell Surface Expressed on Lipopolysaccharide-stimulated Human Blood Monocytes and a Constitutively Tissue Factor-producing Neoplastic Cell Line,”The Journal of Cell Biology(Jul. 1989), vol. 109, pp. 389-395, The Rockefeller University Press.
Ran, S. et al. “Infarction of Solid Hodgkin's Tumors in Mice by Antibody-directed Targeting of Tissue Factor to Tumor Vasculature,”Cancer Research(Oct. 15, 1998), pp. 4646-4653.
Bellamy, W. et al. “Development of an orthotopic SCID mouse-human tumor xenograft model displaying the multidrug-resistant phenotype,”Cancer Chemother Pharmocol(1996), vol. 37, pp. 305-316.
Huang, X. et al. “Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature,”Science(Jan. 24, 1997), vol. 275, pp. 547-550.
Morrissey, J. “Molecular Cloning of the cDNA for Tissue Factor, the Cellular Receptor for the Initiation of the Coagulation Protease Cascade,”Cell(Jul. 3, 1987), vol. 50, pp. 129-135, Cell Press.
Davie, et al., “Waterfall Sequence for Intrinsic Blood Clotting,”Science, vol. 145, pp. 1310-1312 (1964), USA.
Giesen, et al., “Blood-borne tissue factor: Another view of thrombosis,”Proc. Natl. Acad. Sci., vol. 96, pp. 2311-2315 (1999), Medical Sciences, USA.
Taylor, et al., “LethalE. coliSeptic Shock is Prevented by Blocking Tissue Factor With Monoclonal Antibody,”Circulatory Shock, vol. 33, pp. 127-134 (1991), Wiley-Liss, Inc., USA.
MacFarlane, “Haemotology, An Enzyme Cascade in the Blood Clotting Mechanism, and its Function as a Biochemical Amplifier”,Nature, vol. 202, pp. 498-499 (1964), USA.
Pawashe, et al., “A Monoclonal Antibody Against Rabbit Tissue Factor Inhibits Thrombus Formation in Stenotic Injured Rabbit Carotid Arteries,”Circulation Research, vol. 74, No. 1, pp. 56-63 (1994), USA.
Levi, et al., “Inhibition of Endotoxin-induced Activation of Coagulation and Fibrinolysis by Pentoxifylline or by a Monoclonal Anti-tissue factor Antibody in Chimpanzees,”The Journal of Clinical Investigation, Inc., vol. 93, pp. 114-120 (1994), USA.
Huang, et al., “Tumor Infarction in Mice by Antiboby-Directed Targeting of Tissue Factor to Tumor Vasculature,”Science, vol. 275, pp. 547, 550 (1997).
Holst, et al., “Local Application of Recombinant Active-site Inhibited Human Clotting Factor VIIa Reduces Thrombus Weight and Improves Patency in a Rabbit Venous Thrombosis Model,”Eur J Vasc Endovasc Surg, vol. 15, pp. 515-520 (1998), W.B. Saunders Company Ltd., USA.
Bellamy, et al., “Development of an orthotopic SCID mouse-human tumor xenograft mocjel displaying the multidrug-resistant phenotype,”Cancer Chemother Phamracol, vol. 37, pp. 305-316 (1996), Springer-Verlag, Germany.
Randolph, et al., “Role of Tissue Factor in Adhesion of Mononuclear Phagocytes to and Trafficking Through Endothelium In Vitro,”Blood, vol. 92, No. 11, pp. 4167-4177 (1998), The American Society of Hematology, USA.
Himber, et al., “Dissociation of Antithrombotic Effect and Bleeding Time Prolongation in Rabbits by Inhibiting Tissue Factor Function,”Thromb Haemost, vol. 78, pp. 1142-1149 (1997), Schattauer Verlag, Germany.
Ragni, et al., “Monoclonal Antibody Against Tissue Factor Shortens Tissue Plasminogen Activator Lysis Time and Prevents Reocclusion in a Rabbit Model of Carotid Artery Thrombosis,”Circulation, vol. 93, No. 10, pp. 1913-1918 (1996), American Heart Association, Inc., USA.
Morrissey, et al., “Molecular Cloning of the cDNA for Tissue Factor, the Cellular Receptor for the Initiation of the Coagulation Protease Cascade,”Cell, vol. 50, pp. 129-135 (1987), Cell Press, USA.
Ran, et al., “Infarction of Solid Hodgkin's Tumors in Mice by Antibody-directed Targeting of Tissue Factor to Tumor Vasculature,”Cancer Research, vol. 58, pp. 4646-4653 (1998), USA.
Drake, et al., “Functional Tissue Factor is Entirely Cell Surface Expressed on Lipopolysaccharaide-stimulated Human Blood Monocytes and a Constitutively Tissue Factor-producing Neoplastic Cell Line,”The Journal of Cell Biology, vol. 109, pp. 389-395 (1989), The Rockefeller University Press, USA.
Callander, et al., “Immunohistochemical Identification of Tissue Factor in Solid Tumors,”Cancer, vol. 70, pp. 1194-1201 (1992), USA.
Konigsberg, et al., “The TF: VIIa Complex: Clinical Significance, Structure-function Relationships and Its Role in Signaling and Metastasis,”Thromb Haemost, vol. 86, pp. 757-771 (2001), Schattauer GmbH, Germany.
Harker, et al., “Antithrombotic and Antilesion Benefits without Hemorrhagic Risks by Inhibiting Tissue Factor Pathway,”Haemostasis, vol. 26, pp. 76-82 (1996), S. Karger AG, Switzerland.
Hougie, “Reactions of Stuart Factor and Factor VII with Brain and Factor V”,P.S.E.B.M., vol. 101, pp. 132-135 (1959), National Heart Institute, USA.
Nakayama, et al., “Anticoagulation Therapy by Inhibiting Extrinsic Pathway”,Translation of Hematology&Oncology, vol. 39, No. 4, pp. 298-302 (1999), First Department of Internal Medicine, Nagoya University School of Medicine, Japan.
Mohri, M. et al., The antithrombotic effects of recombinant human soluble thrombomodulin (rhs TM) on tissue factor-induced disseminated intravascular coagulation in crab-eating monkeys (Macaca fascicularis); Blood Coagulation arid Fibronolysis, vol. 8,pp. 274-283, 1997 Rapid Science Publishers.
Bromberg, M. E., et al., “Role of Tissue Factor in Metastatsis: Functions of the Cytoplasmic and Extracellular Domains of the Molecule” Trombosis and Haemostasis, Stuttgart, DE, vol. 82, pp. 88-92 (Jul. 1999).
Carmeliet, P., et al., “Molecules in focus. Tissue factor”, International Journal of Biochemistry and Cell Biology, vol. 30, No. 6, pp. 661
Hattori Kunihiro
Kitazawa Takehisa
Saito Hiroyuki
Yoshihashi Kazutaka
Bunner Bridget E
Chugai Seiyaku Kabushiki Kaisha
Foley & Lardner LLP
Hamud Fozia
LandOfFree
Prevention and treatment of diseases associated with blood... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prevention and treatment of diseases associated with blood..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prevention and treatment of diseases associated with blood... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4279062